Sign Up to like & get recommendations! 1
Published in 2022 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51599
Abstract: The present study was intended to analyze the characteristics of myelinated nerve fibers density (MFD) of transthyretin amyloid polyneuropathy (ATTR‐PN) and other similar neuropathies. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13847
Abstract: It has been reported that a staging system combining N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T (hs‐cTnT) or estimated glomerular filtration rate (eGFR) is useful in patients with wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM). However,… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13884
Abstract: Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is a more common disease than previously thought. Awareness of ATTRwt CM and its diagnosis has been challenged by its unspecific and widely distributed clinical manifestations and traditionally invasive… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13909
Abstract: To clarify the usefulness of left atrial (LA) function and left ventricular (LV) function obtained by two‐dimensional (2D) speckle tracking echocardiography to diagnose concomitant transthyretin amyloid cardiomyopathy (ATTR‐CM) in patients with aortic stenosis (AS). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13961
Abstract: Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to describe… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14188
Abstract: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14350
Abstract: Transthyretin amyloid cardiomyopathy (ATTR CM) is a progressive and severe heart disease with physical and psychological implications. The Nordic PROACT study was conducted to investigate the health‐related quality of life (HRQoL) in ATTR CM patients. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)31447-9
Abstract: Transthyretin amyloid cardiomyopathy (ATTR-CM) may be more common than previously thought and is often underdiagnosed. We sought to evaluate traditionally accepted “red flag” clinical features with novel methods. We identified a random sample of 46… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Europace"
DOI: 10.1093/europace/euad105
Abstract: Abstract Aims This study aimed to identify factors for attention leading to future pacing device implantation (PDI) and reveal the necessity of prophylactic PDI or implantable cardioverter-defibrillator (ICD) implantation in transthyretin amyloid cardiomyopathy (ATTR-CM) patients.… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "Journal of Internal Medicine"
DOI: 10.1111/joim.13222
Abstract: Wild‐type transthyretin (ATTRwt) amyloidosis is the most common systemic amyloidosis in Western countries and manifests mainly as progressive restrictive cardiomyopathy. read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Cardiology"
DOI: 10.1159/000455089
Abstract: Tafamidis meglumine is a novel medicine that has been shown to slow the progression of peripheral neurological impairment in patients with hereditary transthyretin amyloidosis (ATTR). However, the efficacy of tafamidis against ATTR-related cardiac amyloidosis remains… read more here.